Press Releases

DAY HI:
DAY LOW:
VOLUME:

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Mar 07, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
Mar 06, 2014
Total revenues for the year ended December 31, 2013 were $155.9 million . Total revenues for the three months ended December 31, 2013 were $41.5 million . Q4 Non-GAAP diluted EPS was $0.05 , and GAAP basic and diluted EPS was ( $0.63 ); the difference is primarily due to non-cash charges.
Feb 27, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to
Feb 06, 2014
FDA grants Priority Review Designation FDA decision date based on PDUFA set for August 9, 2014 HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology
Jan 09, 2014
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
Dec 18, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) announced today the pricing of its offering of $100 million aggregate principal amount of 2.75% convertible senior notes due 2018 (the "Convertible Notes"). The Convertible Notes will be offered and sold in a
Dec 16, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) announced today that it intends, subject to market and other conditions, to offer $100 million aggregate principal amount of convertible senior notes due 2018 (the "Convertible Notes").
Dec 11, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced encouraging clinical data from investigator-sponsored studies of
Dec 10, 2013
Filed for Accelerated Approval with a request for Priority Review. Response from the FDA regarding acceptance to file is expected within 60 days from the FDA receipt date. Over 1,000 patients have been exposed to belinostat across the development program that included 14 Sponsor-initiated studies
Dec 06, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced key presentations of clinical and scientific data at the 55th
Nov 12, 2013
Total revenues for the three months ended September 30, 2013 were $42.4 million as compared to $33.2 million the previous quarter. Non-GAAP EPS was $0.02 , and GAAP EPS was ( $0.13 ). Marqibo ® (vinCRIStine sulfate LIPOSOME injection) successfully launched in September.
Nov 11, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
Nov 08, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to
Oct 30, 2013
Expected NDA filing mid-2014. Granted Orphan designation by the FDA as a conditioning treatment for use in autologous transplant for patients with multiple myeloma. If approved, will be the only drug approved for this indication. In a previous clinical study, Captisol-enabled melphalan met the
Sep 04, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
Sep 03, 2013
Marqibo being launched through Spectrum's existing hematology sales force in the United States . Two ongoing Phase 3 trials evaluating Marqibo in additional indications. Spectrum obtained world-wide marketing rights to Marqibo through the recent acquisition of Talon Therapeutics, Inc.
Aug 07, 2013
Total revenues for the three months ended June 30, 2013 were $33.2 million . The company recorded a GAAP EPS loss of ( $0.17 ), and Non-GAAP loss of ( $0.08 ). Marqibo® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion is planned to be launched in Q4 through Spectrum's existing
Aug 01, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to
Jul 17, 2013
Acquisition adds a novel FDA -approved hematology product to Spectrum's portfolio. Marqibo ® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion is expected to be launched later this year through Spectrum's existing hematology sales force.
Jul 02, 2013
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial
Displaying 161 - 180 of 777